Report Highlights

Spain Smart Inhalers: Market Overview

Spain's smart inhaler market is shaped by the structural reality of the Sistema Nacional de Salud (SNS), a decentralised public health system in which 17 autonomous communities hold independent procurement and formulary authority. This fragmentation means national market size figures mask significant regional disparity: Catalonia, Madrid, and Andalucía together account for an estimated 61% of connected inhaler deployments, while smaller regions such as La Rioja and Cantabria have had minimal adoption. Asthma affects over 3 million Spaniards and COPD accounts for more than 35,000 annual hospitalisations, creating a clinically validated demand base that health economists have repeatedly used to argue for digital adherence tools. Private sector actors, particularly Propeller Health and Adherium, have driven product development and pilot design, while the public SNS has been the gatekeeper of scale.

The current market structure reflects a transitional phase in which pilot-scale deployments funded through regional innovation budgets coexist with nascent commercial arrangements between pharmaceutical companies and hospital networks. AstraZeneca and Boehringer Ingelheim have embedded connected device compatibility into their existing respiratory portfolios, bundling smart inhaler technology with drug contracts to bypass traditional medical device procurement routes. Digital health platform interoperability with Spain's HCDSNS — the shared electronic health record system managed by the Ministerio de Sanidad — remains limited, which constrains data integration and slows clinical validation required for broader reimbursement decisions. The private insurance sector, led by Sanitas and Adeslas, represents a growing but still secondary demand channel, accounting for an estimated 18% of current smart inhaler revenue.

Policy-Driven Growth in Spanish Smart Inhalers

Spain's Plan de Acción para la Salud Digital 2021–2026, published by the Ministerio de Sanidad, explicitly identifies digital therapeutics and connected medical devices as strategic priorities for chronic disease management. While the plan does not create direct procurement mandates, it established the framework for the Red de Ciudades de Salud Digital programme, through which Catalonia, Andalucía, and the Basque Country have received co-financed implementation budgets for digital health pilots. The Estrategia en EPOC del SNS, updated in 2022, named medication adherence monitoring as a tier-one clinical objective, creating a policy rationale that regional health departments have used to justify smart inhaler expenditure within their chronic obstructive disease management allocations — a mechanism that directly translates clinical strategy into procurement spending at the autonomous community level.

The EU Medical Device Regulation (MDR) 2017/745, fully enforced in Spain from May 2021 via the Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), has had a dual policy impact: it raised the compliance bar for manufacturers but simultaneously created a trust signal that Spanish public procurement officers require before approving connected device contracts. Spain's participation in the European Health Data Space (EHDS) regulation, adopted by the European Parliament in 2024, will compel the SNS to build standardised health data infrastructure by 2027 — infrastructure that directly enables smart inhaler data integration with patient records. Additionally, the Ley 4/2022 de Economía Circular and associated green procurement guidelines are beginning to influence inhaler procurement criteria, with device recyclability and carbon footprint now formally listed as secondary award criteria in several Catalan hospital tenders, nudging suppliers toward connected devices that reduce overall inhaler consumption through better adherence.

Regulatory Barriers and Compliance Costs

The primary regulatory barrier for smart inhaler market entry in Spain is the AEMPS classification and certification process under EU MDR 2017/745. Devices with software components that influence clinical decisions are classified as Class IIa or IIb medical devices, requiring a notified body conformity assessment that typically takes 12 to 18 months and costs between €150,000 and €400,000 for a mid-sized manufacturer. AEMPS, operating under the Ministerio de Sanidad, also requires Spanish-language labelling and instructions for use that are fully compliant with Real Decreto 192/2023, which updated national rules for medical device market surveillance. Manufacturers without established Spanish legal entities must appoint an EU-authorised representative, adding operational overhead that disproportionately affects non-European entrants seeking to access Spanish regional tenders.

A second significant barrier is the absence of a dedicated digital therapeutic reimbursement pathway under the Cartera de Servicios del SNS, governed by Real Decreto 1030/2006. Unlike Germany's DiGA fast-track framework, Spain has not established a national mechanism through which software-as-a-medical-device products can achieve provisional reimbursement while clinical evidence is being generated. This forces smart inhaler companies to negotiate individually with each of the 17 autonomous community health services — a process that routinely extends 24 to 36 months per region and requires separate health economic dossiers tailored to each community's own budget impact models. Local content rules do not formally apply, but procurement scoring criteria in several regions apply positive weighting to devices with Spanish clinical trial data or established local distribution partnerships, effectively creating an informal localisation requirement that raises market entry costs further.

Policy-Created Opportunities in Spain

The Spanish government's NextGenerationEU implementation plan, administered through the Plan de Recuperación, Transformación y Resiliencia (PRTR), allocated €1.1 billion to health system digital transformation through the Componente 18 funding stream. Within this allocation, the Ministerio de Sanidad designated specific tranches for chronic disease digital management tools, and several autonomous communities — notably Andalucía with its Plan Andaluz de Salud Digital — have used these funds to issue procurement calls that explicitly include connected respiratory device platforms. Manufacturers that can demonstrate interoperability with the Spanish HCDSNS electronic health record and compliance with the HL7 FHIR data standard preferred by the Ministerio de Sanidad are positioned to win contracts within the current PRTR spending window, which requires project completion by December 2026, creating a compressed but high-value procurement timeline.

A second major policy-created opportunity lies in Spain's commitment to the European Health Data Space regulation, which requires member states to enable secondary use of health data for research and public health purposes by 2027. This regulatory deadline is driving the Ministerio de Sanidad to invest in patient-consented data collection infrastructure that smart inhalers are uniquely positioned to supply. Pharma companies with dual drug-device respiratory portfolios — particularly AstraZeneca with its Symbicort and Breztri products and GSK with Ellipta-platform inhalers — are negotiating population health data partnerships with Spanish regional health authorities that effectively monetise adherence datasets as a secondary revenue stream alongside device sales. The upcoming revision of the Estrategia de Atención al Paciente Crónico, expected in 2026, is also anticipated to formally recommend connected inhaler use in COPD management protocols, which would trigger mandatory consideration in all SNS clinical pathways.

Market at a Glance

Leading Market Participants

• Propeller Health (ResMed)
• Adherium
• AstraZeneca
• Boehringer Ingelheim
• GlaxoSmithKline
• Novartis
• Teva Pharmaceutical Industries
• Cohero Health
• Sanitas (digital health division)
• Chiesi Farmaceutici

Regulatory and Policy Environment

The primary legislative framework governing smart inhalers in Spain is EU Regulation 2017/745 on Medical Devices (MDR), transposed and enforced nationally through Real Decreto 192/2023, with AEMPS serving as the competent authority for market surveillance, post-market monitoring, and vigilance reporting. Smart inhalers with dose-tracking software that provides clinical decision support are classified under MDR Rule 11 as Class IIa devices, mandating third-party conformity assessment by a notified body — in Spain, the Asociación Española de Normalización (UNE) holds relevant designation. Manufacturers must also comply with Spain's Ley Orgánica 3/2018 de Protección de Datos Personales (LOPDGDD) and the EU General Data Protection Regulation for any patient health data transmitted via Bluetooth or cloud platforms, with the Agencia Española de Protección de Datos (AEPD) holding enforcement authority. Compared to regional peers, Spain's framework is more stringent than Portugal's and broadly equivalent to France's, but lacks Germany's DiGA provisional reimbursement pathway, placing Spain behind in creating market pull for digital therapeutics.

Upcoming regulatory changes expected to reshape the compliance landscape include the full implementation of the European Health Data Space regulation by 2027, which will require AEMPS to establish data governance protocols for real-world respiratory device data, and the anticipated revision of the Cartera de Servicios del SNS scheduled for consultation in 2026. Industry groups including Fenin (Federación Española de Empresas de Tecnología Sanitaria) have formally submitted proposals to the Ministerio de Sanidad requesting a DiGA-equivalent digital health product listing process, and parliamentary questions filed in the Congreso de los Diputados in 2024 have raised the absence of a national reimbursement pathway as a competitiveness concern. If the 2026 revision incorporates a provisional reimbursement mechanism — even limited to COPD indications — it will fundamentally accelerate the market adoption cycle across all 17 autonomous communities simultaneously, removing the current region-by-region negotiation burden that suppresses overall market growth.

Long-Term Policy Outlook for Spanish Smart Inhalers

By 2032, the most consequential policy shift for Spain's smart inhaler market will be the implementation of the European Health Data Space regulation, which compels the Ministerio de Sanidad to operationalise standardised respiratory health data flows between patient-facing devices and the national HCDSNS infrastructure. This creates a structural pull for connected inhalers as the primary data-generation endpoint in respiratory care pathways. Simultaneously, Spain's commitments under the EU Mission on Cancer and the EU4Health programme, in which Spain participates as a recipient of coordinated funding, are directing additional resources toward prevention and chronic disease monitoring — budget streams that respiratory digital health tools are well-positioned to capture if regulatory classification aligns with programme eligibility criteria being finalised by the European Commission through 2026 and 2027.

The decentralised nature of Spain's SNS means that policy adoption will continue to be geographically uneven through 2032, but convergence is expected as the PRTR-funded digital infrastructure investments create a common technical foundation across autonomous communities. The Basque Country's Osakidetza health service and Catalonia's ICS are the most likely early adopters of any national reimbursement framework, given their existing digital health governance structures and established relationships with smart inhaler manufacturers. Market participants should plan for a two-speed adoption environment through 2028, after which EHDS compliance requirements and a probable revision to the Estrategia en EPOC will bring lagging regions into alignment. Companies that have established clinical evidence and reimbursement agreements with leading regions by 2027 will hold a durable first-mover advantage in what becomes, effectively, a national formulary environment from 2029 onward.

Market Segmentation

By Product Type

• Smart Inhalers with Integrated Sensors
• Add-On Sensor Attachments
• Bluetooth-Enabled Metered-Dose Inhalers
• Dry Powder Smart Inhalers
• Nebuliser-Based Connected Devices

By Disease Indication

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Allergic Rhinitis with Comorbid Asthma
• Pulmonary Fibrosis
• Other Respiratory Conditions

By End User

• Hospital and Specialist Clinics
• Primary Care Centres
• Home Care and Self-Management
• Private Insurance Networks
• Telehealth Platforms

By Distribution Channel

• SNS Public Procurement
• Hospital Pharmacy
• Retail and Community Pharmacy
• Direct-to-Patient Digital Platforms
• Pharma-Bundled Drug-Device Programmes

Frequently Asked Questions

Q1. Which Spanish regulatory agency is responsible for approving smart inhalers, and what classification do they typically receive? ▼

AEMPS, the Agencia Española de Medicamentos y Productos Sanitarios, is the competent authority under EU MDR 2017/745 enforced via Real Decreto 192/2023. Smart inhalers with clinical decision-support software are typically classified as Class IIa medical devices, requiring notified body conformity assessment before market access.

Q2. Is there a national reimbursement pathway for smart inhalers under Spain's Sistema Nacional de Salud? ▼

No national reimbursement pathway currently exists for software-as-a-medical-device products under the Cartera de Servicios del SNS governed by Real Decreto 1030/2006. Reimbursement decisions are made independently by each of the 17 autonomous community health services, requiring separate negotiation and health economic submissions per region.

Q3. How does the EU Medical Device Regulation affect the timeline and cost for smart inhaler market entry in Spain? ▼

EU MDR 2017/745 enforcement by AEMPS requires Class IIa notified body assessment costing €150,000 to €400,000, with timelines of 12 to 18 months. Manufacturers must also comply with Real Decreto 192/2023 on Spanish-language labelling and LOPDGDD data protection requirements enforced by the AEPD.

Q4. What role does the Plan de Recuperación, Transformación y Resiliencia play in smart inhaler procurement? ▼

The PRTR's Componente 18 funding stream allocated resources to health system digitalisation, enabling autonomous communities such as Andalucía to issue procurement calls for connected respiratory devices. Projects must reach completion by December 2026, creating a time-limited but significant public procurement opportunity for compliant smart inhaler vendors.

Q5. How will the European Health Data Space regulation affect Spain's smart inhaler market through 2032? ▼

The EHDS regulation, adopted in 2024, requires Spain to establish standardised health data infrastructure by 2027, compelling the Ministerio de Sanidad to enable respiratory device data integration with the HCDSNS national electronic health record. This creates a structural requirement for connected inhaler compatibility that will become a de facto procurement criterion across autonomous community tenders.